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S U M M A R Y
Following the HIV epidemic, several countries have reported co-infections of Leishmania with HIV. Co-
infection with these two pathogens results in rapid disease progression, more severe disease, and a poor
response to treatment. A systematic review of the literature from India is presented herein. Since the ﬁrst
case of visceral leishmaniasis (VL) and HIV was published from India in 1999, a number of cases of HIV–
Leishmania co-infection have been reported, but the proportion has been low (0.029–0.4%), as also
reported in other countries where these two diseases are co-endemic. More than 89 cases of VL–HIV and
10 cases of cutaneous leishmaniasis (CL)–HIV have been published since 1999. Of these latter 10 cases,
ﬁve had simple CL and ﬁve cases manifested with diffuse cutaneous leishmaniasis (DCL). In addition, one
case of post-kala-azar mucocutaneous leishmaniasis in a patient with full-blown AIDS has also been
reported. In two cases, it could not be ascertained whether they were cases of DCL or post-kala-azar
dermal leishmaniasis from the description. Although the ﬁrst case of VL–HIV co-infection was reported
from the sub-Himalayan state of Uttarakhand, most cases have been reported from the VL endemic state
of Bihar. HIV–Leishmania is not alarmingly high in India. Most cases were found to have occurred during
1997–2007. After that, the number of new cases decreased. This is most probably due to the low
prevalence of HIV in VL and CL endemic regions and to the free supply of highly active antiretroviral
therapy for HIV-infected patients.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Leishmaniasis is a parasitic disease caused by the haemo-
ﬂagellate parasite, Leishmania spp.1,2 Leishmania is one of several
genera within the family Trypanosomatidae, characterized by the
possession of kinetoplast DNA (kDNA).3,4 There are more than
20 species of Leishmania that can cause human infection. Female
sandﬂies belonging to the genus Phlebotomus and its six subgenera
are the main vectors in the Old World3 and the genus Lutzomyia in
the New World.4 On rare occasions, transmission may occur
congenitally or as a result of blood transfusion.5
Leishmaniasis manifests mainly in three forms: visceral
leishmaniasis (VL), cutaneous leishmaniasis (CL), and mucocuta-
neous leishmaniasis (MCL). VL is the most severe form of the
disease and is often fatal if not treated.6 Globally the disease is
endemic in 98 countries on ﬁve continents, with a total of
310 million people at risk. According to a World Health* Tel.: +91 11 26594977/26588484; fax: +91 11 26588641/26588663.
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http://dx.doi.org/10.1016/j.ijid.2014.07.011
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Organization (WHO) estimate, 1.3 million new cases of leishmani-
asis occur worldwide annually. This review focuses on the
epidemiology of HIV and leishmaniasis in India, the immunological
events that take place during co-infection with these two
pathogens, and the challenges we face in diagnosing AIDS-
associated leishmaniasis.
2. Epidemiology of visceral leishmaniasis in India
Of all cases of VL reported in the world, 90% occur in six
countries: India, Bangladesh, Brazil, Ethiopia, South Sudan, and
Sudan.1,2 The word kala-azar was ﬁrst used in India, and before this
term was coined, the manifestations of this disease were known by
various other names.7 The causative agent of kala-azar remained
unknown for several decades. In 1903, Major W.B. Leishman, who
was posted in the Dum-Dum area of Calcutta (eastern India),
published his microscopic observations in an issue of the British
Medical Journal. He thought that he had observed trypanosomes.
Two months later, Prof. Charles Donovan, Professor at the Madras
Medical College, Madras (southern India), suggested that theciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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the same journal, Sir Ronald Ross, recognizing the contribution of
both of these doctors, named the parasite Leishmania donovani.8
During the ﬁrst 50 years of the twentieth century, kala-azar
moved from the southern parts of India and remained endemic
only in the eastern states of Assam, Bengal, and Bihar until the late
1990s. More recently, the epidemiology of Indian VL showed a shift
east to west along the Ganges river, and new foci have been
reported in eastern Uttar Pradesh,9 Uttarakhand,10 and Himachal
Pradesh.11 Interestingly, these foci have now become endemic for
VL.12 Sporadic cases have also been reported recently from Madhya
Pradesh (central India),13 Gujarat (western India),14 Haryana
(north India),5 and also from southern states of India15 (Figure 1).
Many of these cases could be associated with migration and
blood transfusion, but in several of these cases, no obvious non-
vector route could be established. Only two possible explanations
could be proposed for this spread to sub-Himalayan and other
parts of India. Either the infection has come from Nepal via some
snow animal reservoirs, or through sandﬂy vectors, possibly
transported to this region. These new foci also lead to questions16
on the dictum that post-kala-azar dermal leishmaniasis (PKDL)
patients are the only reservoirs for new outbreaks and that Indian
VL has an only anthroponotic cycle.17
In southern Europe and Mediterranean countries, VL is caused by
Leishmania infantum, a zoonotic parasite, and is predominantly an
urban and peri-urban disease.1 In India, kala-azar is caused by L.
donovani and is a rural poor man’s disease.18 It more commonly
occurs in socially less privileged communities residing on the
outskirts of villages, providing more accessibility to the sandﬂy. The
two parasite species are signiﬁcantly different in several respects.
While L. infantum is transmitted by Phlebotomus perniciosus,
Phlebotomus ariasi, Phlebotomus neglectus, etc., L. donovani is mainly
transmitted by Phlebotomus argentipes. L. infantum has a zoonotic
cycle, while for L. donovani, no animal cycle has been proved and as
yet it is considered to be an anthroponotic cycle only, althoughFigure 1. Diagrammatic representation of the spread of HIV-1 from primary foci
(dark red spots) to the respective states (red) in southern and western India and
eventually to the whole country. Primary foci of Leishmania donovani (dark green
spots) in eastern states (green) of India spread upward to other parts of the country
and became established as a new focus in the sub-Himalayan state (green dots) of
Uttarakhand. Cutaneous leishmaniasis caused by Leishmania tropica remained
endemic to Rajasthan State (yellow), but recently the disease has spread to the sub-
Himalayan state of Himachal Pradesh and far south.recently some goats have been incriminated as possible reservoirs of
L. donovani in India.19
Young children are more vulnerable and show severe disease
manifestations due to malnutrition and a weak immune defence
system.20 The disease is characterized by irregular bouts of fever,
substantial weight loss, swelling of the spleen and liver, and gross
anaemia. In some areas of India, lymphadenopathy is reported in as
many as 50% of cases.12 Although people are often bitten by
sandﬂies infected with Leishmania protozoa, most do not develop
the disease and remain asymptomatic yet latently infected.21
However, disease presentations are severe among persons who are
immunosuppressed, e.g. after organ transplantation,22 haemato-
logical malignancy,23 auto-immune diseases,24 and advanced HIV
disease.25
3. Epidemiology of HIV infection in India
HIV, the causative agent of AIDS, reached India within 3 years of
its discovery in 1983. The ﬁrst HIV-1-seropositive case was
diagnosed in April 1986 in Tamil Nadu State of south India26,27 and
the ﬁrst clinical case of AIDS was diagnosed in Bombay in the same
year.28 However, the virus spread very fast to other neighbouring
areas and soon a sharp increase in HIV incidence was noted
(Figure 1). Within the next 3 years, the prevalence of HIV had
increased from 1.8% to 28.6% in commercial sex workers,29 and to
16.3% in professional blood donors in Tamil Nadu.30 Seeing this
rapid spread, the Government of India set up a national HIV
surveillance program.31,32 The surveys carried out by the Indian
Council of Medical Research (ICMR) showed that almost all cases
were HIV-1 and only 1.3% were HIV-2 monoinfections. In 1.5% of
cases, HIV-1 and HIV-2 dual infections were detected.33 The HIV
infection started spreading to the rest of India mostly through the
migratory population.29,34 However, rural India by and large
remained free of HIV until 1996.35 Nevertheless, its spread was
very slow to north India, where leishmaniasis has been endemic.
The number of HIV cases continued to increase in India until 2006,
at which point India had its maximum number of persons living
with HIV (2.52 million). From 2006 onwards, the Government of
India instituted several preventative measures, including highly
effective information, education, and communication (IEC), safe
blood transfusion, opt-out diagnostic services, and programmatic
administration of highly active antiretroviral therapy (HAART). All
of these measures resulted in a steady decline in new HIV
infections. The 2013 data show that the number of persons living
with HIV in India has come down to 2.1 million.36
4. Immunology of Leishmania–HIV co-infection
Leishmania co-infection has emerged as a major complication in
patients infected with HIV. HIV and VL are locked in a vicious circle of
mutual reinforcement. In HIV-infected persons, VL quickly accel-
erates the onset of AIDS and shortens their life-expectancy.37,38Also,
HIV increases the risk of clinical VL more than 100 times.18,39 This
duo produces a cumulative deﬁciency in the CD4+ T cell-dependent
immune response, exponentially increasing disease severity and
their consequences. A paradigm shift in cytokine networking also
takes place (Figure 2). In the Mediterranean region and Europe, VL is
the third most frequent opportunistic infection among HIV-positive
patients.39 For these reasons it was suggested that Leishmania
parasites could be seen as a potential co-factor in HIV-1
pathogenesis.40 Further, it is reported that lipophosphoglycan
(LPG) on the surface of L. donovani amastigotes mediates CD4+ T
cell activation, and Leishmania antigen-induced tumour necrosis
factor alpha (TNF-a) production helps HIV-1 replication.41 This is
further evident from the observation that successful anti-leishman-
ial treatment decreases the HIV viral load.42 Co-infection in THP-1
Figure 2. Schematic diagram depicting the immunological events and cytokine networking that take place during Leishmania donovani infection (panel A), HIV infection
(panel B), and during co-infection of HIV and Leishmania donovani (panel C) in the human host.
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amastigotes in the macrophages. It was shown that a killed HIV
preparation abrogates the proliferative response as well as
interferon gamma (IFN-g) production from the L. donovani
antigen-induced PBMCs of healthy individuals.43,44
5. Epidemiology of Leishmania–HIV co-infection
In the early 1990s a rapidly increasing trend of HIV–Leishmania
was noticed, mainly in Spain and other neighbouring countries,
when the HIV epidemic was at its peak. By 1997, the number of co-
infected patients had peaked. Of the ﬁrst 1700 cases of
Leishmania–HIV co-infection reported to the WHO from 33 coun-
tries, 1440 were from the Mediterranean region,39 mainly from
Spain. During 1998–2001, the incidence of HIV–VL co-infection
plateaued.45 In Spain, most of the infections occurred through
shared injection equipment.46 After 2001, awareness about HIV–
Leishmania co-infection increased, safe injection practices were
promoted, and HAART was administered to most of these patients,
which led to the decline in the number of new cases.45 However, in
Africa, particularly Ethiopia and Sudan, HIV–Leishmania co-
infection is still regarded as an emerging disease.18 In 2013, the
WHO stated that more than 35 countries had reported VL–HIV co-
infection by the year 2012.1
6. Epidemiology of Leishmania–HIV co-infection in India
Curiously no case of Leishmania–HIV co-infection was reported
from India until 1999.10 This is most likely because the HIV
epidemic remained localized to the western and southern parts of
the country, where leishmaniasis is non-existent (Figure 1). Mostcases with a low CD4+ cell count died of tuberculosis or a
tuberculosis-like illness, often due to misdiagnosis. The ﬁrst case of
VL–HIV co-infection was diagnosed at the All India Institute of
Medical Sciences (AIIMS) in 1997 and published in 1999. This case
came from a newly identiﬁed focus of VL in the sub-Himalayan
(Kumaon) region of Uttar Pradesh, now a separate state known as
Uttarakhand. The patient was a 27-year-old truck driver who came
from Almora District. He was misdiagnosed with tuberculosis
because kala-azar was never suspected in this leishmaniasis non-
endemic area.10
Bihar State of India has remained VL endemic for the last several
decades, but interestingly this state was untouched by the HIV
epidemic until the year 1999. In 1999–2000 we carried out a
community-based serosurvey19 to determine the prevalence of
hepatitis B virus (HBV), hepatitis C virus (HCV), and HIV infection
in patients with VL. The study found that of the 4050 inhabitants in
the endemic area, 77 had conﬁrmed leishmaniasis. Although the
prevalence of HBV and HCV co-infections in the VL patients was
extremely high, only one patient (1.3%) was found to be co-infected
with HIV. This patient acquired HIV-1 from a commercial sex
worker in Bombay (or Mumbai), where he used to work as
labourer, and he was most likely the ﬁrst documented case of VL–
HIV co-infection from Bihar. In all probability, several such
migratory labourers brought HIV from Bombay to Bihar.35
During these early years, several subclinical cases of leishman-
iasis21 started manifesting and various workers started publishing
VL–HIV co-infection cases from Bihar and other parts of India.47–60
Thakur et al.47 reported the ﬁrst case of HIV–VL co-infection from
Bihar who was treated successfully with miltefosine. In 2002,
Lanjewar and colleagues48 reported a series of autopsy ﬁndings
from 195 AIDS cases in Bombay. They found that two cases had
S. Singh / International Journal of Infectious Diseases 29 (2014) 103–112106histopathologically conﬁrmed VL. Both were natives of the VL
endemic area of Bihar.
Redhu et al.50 found that out of 25 VL/PKDL cases seen at a Delhi
hospital (AIIMS), six were co-infected with HIV-1. Of these, four were
from the VL endemic state of Bihar, while two were from the newly
identiﬁed focus of VL in Uttarakhand State. Later on, from the same
hospital and in the same year, Mathur et al.51 reported that out of
104 VL cases included in their study, six (5.7%) were HIV-1 co-
infected and one of the six patients was from Uttarakhand. Of note,
there is a strong possibility of an overlap in cases reported by Redhu
et al.50 and Mathur et al.,51 especially the case from Uttarakhand.
In later years, most cases were reported by Sinha and colleagues
from Patna, Bihar.52–54 A major study ﬁnding was that out of
55 VL–HIV cases treated with amphotericin B, 74.5% were cured,
14.5% relapsed, and 10.9% died within 2 years. Others are mostly
case reports55–60 (Table 1). Thus, a total of 89 published records of
VL–HIV cases from India were identiﬁed to the date at which this
manuscript was submitted. There are also a few case reports of VL–
HIV co-infection, but these are not so convincing.55
As well as kala-azar or VL in AIDS patients, at least ﬁve cases of
CL61,62 and ﬁve cases of diffuse CL (DCL)63–67 in HIV-infected
patients have also been reported. Of these 10 cases of tegumentary
leishmaniasis, all CL cases were from the endemic area of
Rajasthan. Of the ﬁve DCL cases, three were from a CL endemic
area, while one was from Kerala and one from Karnataka (Table 2).
Both of the latter states are in southern India and are non-endemic
for VL and CL.
As expected, HIV co-infected Indian patients presented with
atypical manifestations. In 2004 we reported the ﬁrst case of post-
kala-azar mucocutaneous leishmaniasis (PKML). The patient was
treated successfully with antiretrovirals and amphotericin B.68
Later on Kumar et al.54 also reported a case of VL–HIV co-infection
presenting with oral ulcers and Nandi et al.59 reported cases
presenting with cervical lymphadenopathy. This patient was from
VL non-endemic Etah District of Uttar Pradesh. There is confusion
in the classiﬁcation of two cases reported by Shah et al.69. The
authors do not give any reason why they identiﬁed these cases as
PKDL without any suggestive history of VL, rather than DCL.
Out of the total 89 cases of VL–HIV co-infection reported so far
from India, 28 were reported in the ﬁrst 10 years (1997–2006)
following the ﬁrst case diagnosed in 1997. From 2007 to date,
61 more cases were added. In the second 9 years of reports of this
co-infection (2007–2013), 197 332 VL cases70 and 2.1 million HIV
cases were reported to the Government of India. Thus, the rate of
co-infection in these years is estimated to be only 0.029%. The rate
did increase in later years, but it remains very low as compared to
other VL and HIV co-endemic regions, such as southern Europe
(20–40%) and some African countries (up to 70%). Even if we
calculate the rate of HIV and VL cases only for the VL endemic
states of Bihar and Jharkhand (separated from Bihar in 2000), it
comes to only 6.86% per year. The average number of HIV cases in
these two states has been 150 000 for the last 9 years. There could
be several reasons for this low rate in India. The most important is
the low rate of intravenous drug use46 in VL endemic areas and the
predominance of orthodox populations in northern India, which
has witnessed a slow spread of HIV as compared to western and
southern India. In VL endemic states, the incidence rate of HIV has
remained <0.3%, while in south Indian states and Maharashtra, it
has remained between 0.5% and 1.2%.71
7. Clinical manifestations and prognosis of Leishmania–HIV co-
infection
In India, the two clinical forms are endemic, VL and CL
(Figure 1). As discussed above, the visceral form is caused by L.
donovani, while the cutaneous form is caused by L. tropica.2 It iswell established that HIV-1 modiﬁes the clinical presentation of
leishmaniasis in co-infected patients, especially those with VL.37–
39 Several atypical species and sub-species of Leishmania have
been incriminated in the infection of HIV-infected subjects and can
be called purely opportunistic species.2,39,50,68 In HIV-associated
leishmaniasis, dermotropic species may disseminate to the
reticuloendothelial system and various other organs including
the viscera, and conversely the visceralizing species can manifest
in an atypical manner. Dissemination is common and a fulminant
presentation of VL is possible. Relapses are normal in these
patients. Several cases of VL–HIV co-infection will not have
splenomegaly.45,72
In India several patients with HIV co-infection are reported to
have shown disease that manifests in an atypical manner, delaying
the diagnosis and management. Tuberculosis is the most common
co-infection in Indian HIV-positive patients and several cases have
been diagnosed with a triple infection of HIV, Leishmania sp, and
Mycobacterium sp;10,49,51,53 many more might have died undiag-
nosed.
Vyas and Shah58 reported probably the ﬁrst case of visceral and
concomitant PKDL in a patient from Rajasthan, an area endemic for
CL only. The patient presented with non-tender papulo-nodular
lesions all over the body and had hepatosplenomegaly and inguinal
lymphadenopathy. Leishman–Donovan (LD) bodies could be
demonstrated in aspirates from lymph node, nodular lesion, blood
buffy coat, and bone marrow. Although the species was not
identiﬁed, since the patient came from a L. tropica endemic region,
L. donovani was less likely in this case. Nandi et al.59 and Mishra
et al.60 also reported lymphadenopathy in their patients as the
presenting clinical feature. Purohit et al.65 reported a case of CL in
HIV-infected patients in whom LD bodies could be demonstrated
in skin as well as in bone marrow aspirate smears. Two cases of DCL
have been reported from non-endemic areas of south India; both
presented with multiple non-tender skin lesions.64,67 L. donovani
and L. tropica have a different pathogenesis. While L. tropica usually
acts purely as an opportunistic infection in HIV-infected patients, L.
donovani is pathogenic in itself. Alvar et al.45 described dissemi-
nated CL to be the major characteristic feature of leishmaniasis in
HIV-positive patients.
Beside the visceral and tegumentary forms, Leishmania species
can manifest in various other atypical forms. Hence, dermatolo-
gists, internists, and clinical microbiologists must be aware of such
atypical manifestations. In 2004, we reported the case of a patient
with Leishmania–HIV co-infection, who presented with multiple
erythematous lesions on the tongue, mucosa of the nasal alae,
conjuctivae, and soft palate, as well as on the skin of the face, after
cured kala-azar.68 The causative agent was L. donovani. No such
manifestations of PKDL have been reported from India. Hence, we
named this condition PKML. The treatment of these co-infected
patients must be planned carefully. HIV-positive patients in India
have a poor treatment success rate (74.5%) with a high relapse rate
(14.5%) and high death rate (10.9%) even with best treatment
regimen.57
8. Leishmania and immune reconstitution syndrome in AIDS
patients
Immune reconstitution syndrome (IRS), or immune restoration
disease (IRD), is deﬁned as an acute symptomatic or paradoxical
deterioration of a pre-existing infection that is temporally related
to the recovery of the immune system. Immune restoration may
occur due to immunopathological damage associated with the
reversal of immunosuppressive processes, such as with HAART for
AIDS.73 The pre-existing microbial infection could be either
asymptomatic or mildly symptomatic. The resulting clinical
manifestations of this phenomenon are diverse and depend on
Table 1
Clinical and demographic characteristics of VL–HIV co-infection in India (1997–2013)
SN Disease
form
No. of VL/VL–
HIV co-infected
Patients
Age,
years
Gender
and M/F
ratio
Geographical origin Visit to VL/CL
endemic area
Clinical presentation
and diagnostic criteria
of Leishmania–HIV
co-infection
CD4/CD8
count,
cells/ml
Treatment Outcome
of VL
Reference
1 VL 5 cases
1 HIV-pos
4 HIV-neg
16–45 4M, 1 F Kumaon (UK)
region of India
Never All had been misdiagnosed as
TB locally; diagnosis of VL
conﬁrmed in Delhi by
demonstrating LD bodies and
anti-rK39 ELISA
ND SAG Cured Singh et al.,
1999 [10]
2 VL 77 VL cases
1 HIV-pos
76 HIV-neg
11–40 80% M Bihar NA Serosurvey for Leishmania–HIV
co-infection carried out in VL
endemic Samastipur District;
conﬁrmed by anti-rK39 ELISA
ND SAG Cured Singh et al.,
2000 [18]
3 VL 1 case Not
given
M Bihar NA rK39 and splenic aspirate ND Miltefosine Cureda Thakur et al.,
2000 [47]
4 VL 195 HIV
cases, 2
had VL
21, 40 76% M Reported from
Mumbai
Both VL cases
from Bihar
Post-mortem histopathological
examination showed LD bodies
in tissues
NA NA NA Lanjewar et al.,
2002 [48]
5 VL 1 case 37 M RMRIMS Patna,
Bihar
NA Triple infection of HIV, VL, and
disseminated TB;
demonstration of LD bodies in
splenic aspirate
310/550 L-Ampho B +
HAART+ ATT
(RHEZ)
Cureda of VL
and TB
Pandey et al.,
2005 [49]
6 VL/ PKDL
casesb
25 cases
6 HIV-pos
19 HIV-neg
2.5–61 76% M AIIMS,
New Delhi
4 from Bihar,
2 from
Uttarakhand
Fever and
hepatosplenomegaly; one
patient had triple infection of
HIV, Leishmania, and
Mycobacterium tuberculosis
ND SAG 5 Cured with
SAG, 1 died
Redhu et al.,
2006 [50]
7 VL/ PKDL
casesb
104 cases
6 HIV-pos
98 HIV-neg
21
(median)
M AIIMS,
New Delhi
5 from Bihar,
1 from
Uttarakhand
Bone marrow aspirate showed
the LD bodies for all patients
23–320 Ampho B/SAG +
miltefosine
No details Mathur et al.,
2006 [51]
8 VL 280 HIV
cases; 8
had VL
1– 45 Both RMRIMS
Patna, Bihar
NA Direct agglutination test and
demonstration of LD bodies in
splenic aspirate; sensitivity of
DAT was 80% and antibody
titres were lower in co-infected
patients
162/840
(mean)
Ampho B/
miltefosine +
HAART
Improved Sinha et al.,
2006 [52]
9 VL 2 cases 40, 40 F, M RMRIMS
Patna, Bihar
NA Splenic aspirate showed LD
bodies for both the patients;
one patient had triple infection
of HIV, Leishmania, and M.
tuberculosis
71/179 8/
143
ART + ATT,
ART +
miltefosine
+ATT
One patient
cureda
Das et al.,
2006 [53]
10 VL 1 case 35 F Etah District
western
Uttar Pradesh
Never Submandibular lymph node
aspirate showed LD bodies;
serological test (ELlSA) for
leishmaniasis was positive;
patient had blood transfusion
10 years ago
12/18 No treatment
could be
initiated
Died on
third day
Kumar et al.,
2007 [54]
11 VL 1 case 55 M RMRIMS Patna,
Bihar
NA Splenic aspirate showed the
presence of LD bodies
180/643 Miltefosine
+ HAART
VL cureda
but died
after
6 months
Pandey et al.,
2008 [55]
12 VL 1 case 32 M Pune No details rK39 RDT done three times
remained negative; bone
marrow aspirate reported to
have LD bodies?
57 L-Ampho B Cureda Yanamandra et al.,
2011 [56]
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fungi.74 The data regarding leishmaniasis-associated IRS from
India and globally are very limited. There are only a few reports,
and these are mostly from non-endemic countries.75,76 From India
there is only a report by Patel et al.77 who described a case of VL
presenting with haemophagocytosis, fever, severe anaemia, and
mild splenomegaly. The patient was put on HAART. His CD4+ cell
count was 234 cells/ml. After 3 months of HAART, the patient
returned with a high-grade fever and mild hepatomegaly but
massive splenomegaly. This time his CD4+ count was only 57 cell/
ml. A bone marrow aspirate revealed severely hypocellular
marrow, myeloid hypoplasia, and megaloblastoid erythroid
maturation with delayed haemoglobinization, but adequate
megakaryocytes. Numerous LD bodies could also be demonstrated
in the aspirate smear. The patient was treated successfully with
amphotericin B.
9. Diagnosis of Leishmania–HIV co-infection
The laboratory diagnosis of HIV infection is well established,
but the diagnosis of leishmaniasis per se, and especially in HIV-
infected persons, may very often, if not always, be difﬁcult. The
clinical signs and symptoms of VL or CL in these patients pose
several problems. Cases of kala-azar in non-endemic areas may be
confused with and misdiagnosed as other similar conditions of
infectious or non-infectious origin.2 Similarly, numerous primary
and secondary skin conditions are frequently over-diagnosed as
early lesions of CL in endemic areas, and in non-endemic countries
CL is frequently misdiagnosed as other diseases. Whenever, there is
a clinical suspicion of leishmaniasis, the diagnosis should be
conﬁrmed by laboratory tests. A standard algorithm has been
suggested for this.78 Tests for both non-speciﬁc surrogate markers
and speciﬁc tests should be taken into account. Amongst, various
surrogate markers, interleukins and TNF-a can be used as
prognostic markers. TNF-a increases signiﬁcantly in acute persis-
tent cases of kala-azar, but the levels come down sharply after
parasitological cure.79 The speciﬁc tests are based on the principle
of detecting the causative agent as a whole, in parts, fragments,
coatings, cellular or molecular products, or its footprints.
The conﬁrmatory diagnosis of leishmaniasis, irrespective of the
patient’s HIV status, relies on the demonstration of parasite in the
tissues of relevance, such as bone marrow, spleen, lymph nodes, or
liver, the peripheral blood buffy coat, slit skin smears, or biopsies,
as published elsewhere.2,78,80 Hence, only special considerations in
the diagnosis of HIV-associated leishmaniasis will be discussed
here.81
The hallmark of VL is hyperimmunoglobulinemia; this is in
contrast to cutaneous and mucocutaneous leishmaniasis in which
the humoral immune response is very poor. However, hyper-
immunoglobulinemia may not be signiﬁcant if the Leishmania
infection has occurred after advanced HIV disease. A number of
antibody detection methods have been developed to measure
these immunoglobulins.2,78,80 Currently tests such as the indirect
immunoﬂuorescence assay (IFA), latex agglutination test (LAT),
direct agglutination test (DAT), various enzyme immunoassays
(EIA), etc., can be used for antibody detection. Antigens of the
parasite can also be detected using these test formats, except DAT.
The sensitivity of the IFA test varies from 70% to 86.6% but it has
high (>90%) speciﬁcity. The direct ﬂuorescence antibody (DFA) test
is more useful in the diagnosis of CL, MCL, and PKDL. In full-blown
AIDS cases, where antibody titres are low and the parasite load is
high, the DFA test may be more useful.2,78 The DAT is a highly
speciﬁc and sensitive test and is endorsed by the WHO for the
diagnosis of VL. The DAT has been found to be 91–100% sensitive
and 72–100% speciﬁc in HIV-negative patients in various
studies.81,82 However, in HIV co-infected patients its sensitivity
Table 2
HIV co-infected patients with non-visceral forms of leishmaniasis reported from India
SN Disease
form
Number
of cases
Age,
years
Gender
and M/F
ratio
Geographical
origin
Visit to VL/CL
endemic area
Clinical presentation
and diagnostic criteria
of Leishmania–HIV
co-infection
CD4/CD8
count,
cells/ml
Treatment Outcome Reference
1 CL 2 cases 35, 42 M Ahmedabad,
Gujarat
Resident of
Rajasthan
and Bihar
LD bodies demonstrated in
skin scraping smears
224 Ketoconazole +ART Only 1 patient
improved
Mittal et al.,
2005 [61]
2 CL 3 cases 40, 34, 28 All M Bikaner,
Rajasthan
NA Skin smear showed LD
bodies
290–380 (In 2) SAG + HAART +
rifampin
1 Died, 1 cured,
1 refused Rx
Soni et al.,
2011 [62]
3 DCL 1 case 38 M Alwar,
Rajasthan
Demonstration of LD bodies
in skin scrapes
95 Ketoconazole + ART Lost to follow-up Chaudhary
et al., 2008 [63]
4 DCL 1 case 30 M Kerala South India Slit smear showed LD
bodies
684 ART + SSG Lost to follow-up Mehta et al.,
2009 [64]
5 DCL 1 case 33 M Jodhpur,
Rajasthan
NA Microscopic examinations
of skin smear and bone
marrow examination
revealed LD bodies
95 Rifampin +
ketoconazole + ART
Died Purohit et al.,
2012 [65]
6 DCL 1 case 32 F Bikaner,
Rajasthan
NA LD bodies on
histopathology, identiﬁed
as Leishmania tropica by
PCR-RFLP
44 SAG +HAART Did not improve
clinically
Khandelwal
et al., 2011 [66]
7 DCL 1 case 45 M Karnataka Never Skin nodules showed LD
bodies
250 No details No details Mahesh et al.,
2012 [67]
8 PKML 1 case 27 M Bihar PKML, anti-RK39, anti-
rKE16 positive
Ampho B + ART Cured Singh, 2004 [68]
9 ? DCL/ PKDL 2 cases 45, 52 M Bikaner,
Rajasthan
One patient
gave history
of visiting Bihar
Demonstration of LD bodies
in tissues
210, 170 Rifampin +
ketoconazole + HAART
No details Shah et al.,
2010 [69]
Ampho B, amphotericin B; ART, antiretroviral therapy; CL, cutaneous leishmaniasis; DCL, diffuse cutaneous leishmaniasis; F, female; HAART, highly active antiretroviral therapy; LD, Leishman–Donovan; M,male; NA, not applicable
as the case(s) were from an endemic area; PKDL, post-kala-azar dermal leishmaniasis; PKML, post-kala-azar-mucosal leishmaniasis; RFLP, restriction fragment length polymorphism; SAG, sodium antimony gluconate; SSG, sodium
stibogluconate; VL, visceral leishmaniasis.
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Table 3
Sensitivity and speciﬁcity of various recombinant and puriﬁed LPG Leishmania proteins in the diagnosis of visceral leishmaniasis using ELISA (95% CI)a
Determinants rKE16b rK39b rKLO8 rH2A rH2B rGBP rLACK rgp63 rP20 rPSA-2- GST rPSA-2- TRI-GST rPSA-2- MBP Puriﬁed LPG
Sensitivity 100% 100% 98.1% 100% 100% 97% 97% 86% 68% 47% 36% 57% 92%
Speciﬁcity 100% 97% 96.1% 91% 92% 92% 84% 90% 95% 96% 85% 97% 92%
PPV 100% 92% 97.2% 80% 82% 82% 68% 76% 83% 81% 46% 88% 81%
NPV 100% 100% 97.4% 100% 100% 99% 88% 96% 89% 83% 79% 86% 97%
LPG, lipophosphoglycan; CI, conﬁdence interval; PPV, positive predictive value; NPV, negative predictive value.
a Source and cross references: references 2, 21, 45, 50, 78, 80, 82, 84.
b Only these two antigens are commercialized in the form of lateral ﬂow rapid test dipsticks.
S. Singh / International Journal of Infectious Diseases 29 (2014) 103–112110was reported to be signiﬁcantly lower in Ethiopian patients (89%)83
and very low in Indian patients (80%).52,57 EIA tests can be
performed easily and are adaptable for use with various antigens.84
The sensitivity and speciﬁcity of EIAs are greatly inﬂuenced by the
antigen and the test format used.80
A major breakthrough in the diagnosis of VL was reported in
1993 by Burns et al.85 These authors characterized a novel kinesin-
related 39 AA protein (Lc-rK39) from Leishmania chagasi.86 Later
our laboratory prepared another novel antigen (Ld-rKE16) from
Indian strains of L. donovani with very high sensitivity and
speciﬁcity.87,88 Other workers have also attempted to prepare good
recombinant antigens,89,90 but with the exception of rK39 and
rKE16, no other antigen has reached a commercial level.90,91 The
sensitivity and speciﬁcity of various test formats using these two
antigens have been evaluated extensively in both immunocompe-
tent and in VL–HIV co-infected patients (Table 3). 50,51,57,68,78
Although there is no signiﬁcant difference in the performance of
EIA-based tests between HIV-positive and HIV-negative VL
patients, in quantitative terms the antibody titres remain several
logs lower in VL–HIV co-infected patients.50
Antigen detection tests would, in principle, provide a better
means of diagnosis of active leishmaniasis, especially in VL–HIV
co-infected patients, as the antigen levels are expected to
theoretically correlate with the parasite load.2,45,50 Attar et al.92
developed a latex agglutination test kit (Katex) to detect antigen in
urine samples, with satisfactory sensitivity and speciﬁcity in
immunocompetent VL patients. This was found to carry a good
prognostic value,50 but its sensitivity in HIV co-infected patients
has been relatively poorer elsewhere. The kit has not yet been
evaluated on Indian VL–HIV co-infected patients. In HIV-negative
Indian VL patients its sensitivity and speciﬁcity rates are reported
to be between 47% and 67%, and between 98% and 99%,
respectively.93
Delayed hypersensitivity is an important feature of tegumen-
tary forms of human leishmaniasis and can be measured by the
leishmanin skin test (LST). The LST is mainly used as an indicator of
the prevalence of CL and MCL in human and animal populations
and for determining the cure of VL.94,95 The positivity rate of the
LST was found to be 14% in active Indian kala-azar cases and 40.3%
in cured VL patients. Even in healthy controls from a VL endemic
area it was (false) positive in 21.6% of cases.96
Molecular biology is increasingly becoming relevant to the
diagnosis and control of infectious diseases. With increased
information on DNA sequences and the advent of ‘nucleic acid
engineering’, a number of strategies have been developed for
diagnostic purposes. A variety of nucleic acid detection methods
targeting species-speciﬁc DNA and/or RNA genes have been
developed.97 Of these gene ampliﬁcation techniques, PCR has
been the most rewarding because of its extremely high
sensitivity, rapidity, and the ability to work with a broad range
of clinical specimens.97,98 Various Leishmania gene target
sequences can be used. These include, 18S-rRNA, small subunit
rRNA (SSU rRNA), cysteine proteinase b, a repetitive genomic
sequence of DNA, the mini-exon (spliced ladder) gene repeat, theb-tubulin gene region, gp63 gene locus, internal transcribed
spacer (ITS) regions, and micro-satellite DNAs such as maxi- and
mini-circles of kDNA.2,97–102 Several studies have reported that
the PCR assay could detect parasitemia a few weeks before the
appearance of any clinical signs or symptoms.99 The speciﬁcity of
PCR on bone marrow aspirates has been reported to be up to
100% and the sensitivity 80–93.3%, as reviewed earlier.2 Also a
modiﬁed form of the PCR, the nested PCR, was found positive in
27 of 29 (93%) samples, while only 20 of 29 (69%) PKDL samples
were positive in the primary PCR assay.100
Molecular techniques are also very useful for genotyping and
speciating the causative strain of Leishmania. Lukes et al.97 and
Quispe-Tintaya et al.99 used a combination of PCR with
ﬂuorescence resonance energy transfer/melting curve analysis
(FRET/MCA) and multilocus enzyme electrophoresis (MLEE) as
molecular advancements in genotyping the Leishmania spp and
redeﬁning the taxonomy and evolutionary history of Leishmania.
These authors could successfully genotype L. donovani complex
into 25 genotypes and postulated that indeed L. donovani complex
has only two species: L. donovani and L. infantum. They also
suggested that L. donovani originated from South America but
diversiﬁed only after migrating to other parts of the world. The
molecular techniques can also be used for tracking the source of
infection and for the purposes of molecular epidemiology.
Researchers have used kDNA restriction fragment length poly-
morphism (RFLP) for ﬁngerprinting the clinical isolates. Such
applications are most useful in contact tracing and ﬁngerprinting
of the disease-causing pathogen.103
In recent years further advances in molecular biology have
taken place, and highly sensitive and quantitative real-time PCR
assays have been developed that can be used for assessing drug
efﬁcacy104 and the disease outcome in HIV-infected patients.105
The sensitivity of PCR in tegumentary leishmaniasis (CL and MCL)
has been reported to be between 71% and 100%.106 Various types of
specimen can be used, such as skin biopsies and dermal scrapings
from the bottom of the ulcer, as well as exudates and syringe-
sucked ﬂuid taken from ulcerative lesions and the blood.107–109
Multiplex PCR can be used whenever infections with more than
one species are suspected.46 PCR can also be used for species,
strain, and genotype identiﬁcation.110,111
10. Which test to opt in HIV–Leishmania co-infected patients?
Various immunological, parasitological, and molecular techni-
ques available for the diagnosis of HIV–Leishmania co-infection
have been evaluated by Deniau et al.112 These authors reported
that PCR is the only promising tool in HIV–Leishmania co-
infections. Bossolasco et al.113 reported that real-time PCR was the
most useful tool not only for the diagnosis but also for the follow-
up of patients co-infected with HIV-1 and Leishmania spp. These
authors found that Leishmania DNA levels correlated with the
clinical course and their measurement before, during, and after
treatment, and were useful in the clinical management of co-
infections particularly in the HAART era. In another study, Cruz
S. Singh / International Journal of Infectious Diseases 29 (2014) 103–112 111et al.46 reported that a Leishmania-speciﬁc nested PCR (Ln-PCR)
done on blood samples was the technique of choice for diagnosis,
monitoring the success of treatment, and predicting relapses in
patients with HIV–Leishmania co-infection. A PCR assay using the
SSU rRNA gene target was assessed for post-therapeutic follow-up,
and the detection of relapses could be predicted in 97% of cases
with peripheral blood and 100% of cases with bone marrow
samples from HIV-infected patients.100
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